Samsung Biologics Co.,Ltd. (KRX:207940)
1,028,000
+2,000 (0.19%)
At close: May 28, 2025, 3:30 PM KST
Samsung Biologics Revenue
Samsung Biologics had revenue of 1.30T KRW in the quarter ending March 31, 2025, with 37.11% growth. This brings the company's revenue in the last twelve months to 4.90T, up 24.95% year-over-year. In the year 2024, Samsung Biologics had annual revenue of 4.55T with 23.08% growth.
Revenue (ttm)
4,898.69B
Revenue Growth
+24.95%
P/S Ratio
14.94
Revenue / Employee
1.03B
Employees
4,770
Market Cap
73.17T
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4,547.32B | 852.73B | 23.08% |
Dec 31, 2023 | 3,694.59B | 693.29B | 23.10% |
Dec 31, 2022 | 3,001.30B | 1,433.29B | 91.41% |
Dec 31, 2021 | 1,568.01B | 403.23B | 34.62% |
Dec 31, 2020 | 1,164.78B | 463.19B | 66.02% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Celltrion | 3,662.23B |
ALTEOGEN | 151.65B |
Yuhan | 2,114.76B |
SK Biopharmaceuticals | 578.00B |
HLB Co., Ltd. | 74.64B |
Peptron | 3.15B |
PharmaResearch | 392.31B |
LigaChem Biosciences | 125.90B |